Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:CRMD NASDAQ:OCS NASDAQ:ORMP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.98+9.1%$1.98$0.98▼$4.46$681.67M0.468.43 million shs6.23 million shsCRMDCorMedix$7.41+3.1%$8.33$6.13▼$14.96$581.31M1.481.75 million shs569,464 shsOCSOculis$10.84$14.54$10.52▼$34.47$628.50M0.44490,268 shs60,499 shsORMPOramed Pharmaceuticals$4.12+3.7%$4.09$1.98▼$5.19$168.63M1.21232,634 shs93,279 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+9.04%-2.69%-18.47%-15.02%+29.29%CRMDCorMedix-2.18%-9.45%-5.89%-5.27%-38.23%OCSOculis-1.99%-5.16%-17.19%-60.55%-40.11%ORMPOramed Pharmaceuticals-4.80%-1.24%-14.44%+2.32%+80.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.98+9.1%$1.98$0.98▼$4.46$681.67M0.468.43 million shs6.23 million shsCRMDCorMedix$7.41+3.1%$8.33$6.13▼$14.96$581.31M1.481.75 million shs569,464 shsOCSOculis$10.84$14.54$10.52▼$34.47$628.50M0.44490,268 shs60,499 shsORMPOramed Pharmaceuticals$4.12+3.7%$4.09$1.98▼$5.19$168.63M1.21232,634 shs93,279 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+9.04%-2.69%-18.47%-15.02%+29.29%CRMDCorMedix-2.18%-9.45%-5.89%-5.27%-38.23%OCSOculis-1.99%-5.16%-17.19%-60.55%-40.11%ORMPOramed Pharmaceuticals-4.80%-1.24%-14.44%+2.32%+80.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52331.50% UpsideCRMDCorMedix 2.75Moderate Buy$14.86100.50% UpsideOCSOculis 2.80Moderate Buy$38.33253.63% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ORMP, OCS, ALLO, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026OCSOculis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/7/2026CRMDCorMedix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$14.00 ➝ $13.006/11/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)6/11/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026OCSOculis JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $23.006/1/2026OCSOculis Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$49.00 ➝ $38.006/1/2026OCSOculis Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.006/1/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$75.00 ➝ $45.006/1/2026OCSOculis HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $26.006/1/2026OCSOculis Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$46.00 ➝ $38.005/20/2026OCSOculis GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K34,083.56N/AN/A$1.30 per share1.52CRMDCorMedix$311.71M1.86$2.06 per share3.59$5.14 per share1.44OCSOculis$1.45M433.45N/AN/A$4.08 per share2.66ORMPOramed Pharmaceuticals$2M84.27$0.09 per share45.96$5.02 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)CRMDCorMedix$163.05M$2.133.48741.00N/A45.25%45.57%24.76%8/6/2026 (Estimated)OCSOculis-$119.44M-$2.13N/AN/AN/A-8,460.67%-56.78%-45.62%8/6/2026 (Estimated)ORMPOramed Pharmaceuticals$64.05M$2.591.59N/AN/AN/A-5.37%-4.83%8/13/2026 (Estimated)Latest ORMP, OCS, ALLO, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026ORMPOramed Pharmaceuticals$0.43N/AN/AN/AN/AN/A8/12/2026Q2 2026ALLOAllogene Therapeutics-$0.16N/AN/AN/A$0.00 millionN/A8/6/2026Q2 2026CRMDCorMedix$0.26N/AN/AN/A$96.04 millionN/A8/6/2026Q2 2026OCSOculis-$0.48N/AN/AN/A$0.23 millionN/A5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/8/2026Q1 2026OCSOculis-$0.49-$0.63-$0.14-$0.61$0.25 million$0.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.256.07%N/A9.65%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65CRMDCorMedix0.332.972.74OCSOculis0.015.185.18ORMPOramed PharmaceuticalsN/A6.456.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%CRMDCorMedix34.18%OCSOculis22.30%ORMPOramed Pharmaceuticals12.73%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%CRMDCorMedix3.50%OCSOculisN/AORMPOramed Pharmaceuticals17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableCRMDCorMedix3078.45 million75.71 millionOptionableOCSOculis257.98 millionN/ANot OptionableORMPOramed Pharmaceuticals1040.93 million33.64 millionOptionableORMP, OCS, ALLO, and CRMD HeadlinesRecent News About These CompaniesInsider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in StockJuly 3, 2026 | insidertrades.comOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25, 2026 | prnewswire.comORMP: View inclusion in Russell indexes as positive that could raise awareness in investment communityJune 18, 2026 | msn.comOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesJune 17, 2026 | prnewswire.comORMP: Strategically acquiring interests in medtech & technology companiesJune 8, 2026 | msn.comOramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment DirectionMay 22, 2026 | seekingalpha.comOramed Pharmaceuticals Inc.May 18, 2026 | marketwatch.comOramed Pharmaceuticals Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMPMay 15, 2026 | benzinga.comOramed Pharmaceuticals IncorporatedApril 15, 2026 | edition.cnn.comOramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38March 27, 2026 | msn.comOramed: Q4 Earnings SnapshotMarch 26, 2026 | stamfordadvocate.comSLifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with OramedMarch 26, 2026 | finanznachrichten.deLifeward Partners with Oramed to Enhance Biotech Portfolio and Drive Path to ProfitabilityMarch 13, 2026 | quiverquant.comQLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyMarch 13, 2026 | globenewswire.comOramed Pharmaceuticals Inc.: Oramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | finanznachrichten.deOramed and Lifeward Announce Strategic TransactionJanuary 13, 2026 | prnewswire.comLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyJanuary 13, 2026 | globenewswire.comOramed stock rises after receiving $18 million payment from ScilexJanuary 7, 2026 | za.investing.comOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsJanuary 7, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBy Dan Schmidt | July 19, 2026AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space SectorBy Jessica Mitacek | July 17, 2026ORMP, OCS, ALLO, and CRMD Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.98 +0.17 (+9.12%) As of 12:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.CorMedix NASDAQ:CRMD$7.41 +0.22 (+3.06%) As of 12:56 PM Eastern This is a fair market value price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Oculis NASDAQ:OCS$10.84 0.00 (0.00%) As of 12:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Oramed Pharmaceuticals NASDAQ:ORMP$4.12 +0.15 (+3.73%) As of 12:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Powering Up: NextEra and Brookfield Build an Off-Grid Empire 2 Unique Space ETFs That Could Upend the Industry DoorDash's Drone Certification Could Reshape Its Delivery Margins Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
